Search
Close this search box.
Abbreviations

Abbreviations

GMB

Adult glioblastoma

pHGG

Paediatric high-grade glioma

UNCAN

EU initiative for understanding cancer

MRI

Magnetic resonance imaging 

SOC

Standard of care

I/O

Immuno-oncology

TTF

Tumour treating fields

Website

Leuven, Belgium

Katholieke Universiteit Leuven - University Hospital Leuven (KUL-UZL)

UZL is one of the participating organisations on behalf of KUL. UZL is the largest Belgian University hospital and has a comprehensive multidisciplinary neuro-oncology team and works together with the Leuven Cancer Institute and Brain Tumor Focus Group and the Leuven Brain Institute.

Structure

What is KUL-UZL’s main role?

Running the retrospective clinical trial to feed data lake on GBM patients treated with immunotherapy approaches. 

Running small scale proof-of-concept phase 0 clinical trial on anti-Gal1-si RNA formulations via transnasal delivery route in the context of DC-based vaccination strategy.

Which work packages is KUL-UZL involved in?

UZL contributes to work packages 2, 5, 7 and 8.

Who will represent KUL-UZL?

Prof. Dr. Steven De Vleeschouwer

Staff neurosurgeon, Professor KU Leuven

Dept. Neurosciences

Structure

Prof. Dr. Sandra Jacobs

Pediatric Hemato-oncologist, Professor  KU Leuven

Dept. Oncology

Structure

Dr. Steven Smeijers

Resident in neurosurgery

Anke Van der Perren

Clinical Research Coordinator

Clinical Trial Center

Lien Solie

Clinical Trial Coordinator

Dept. Neurosurgery

Structure

Veerle Daniëls

Industrial Research Fund Manager

KU Leuven

Structure

GLIOMATCH Partners